基因组测序分类器在细胞学不确定的嗜酸细胞性甲状腺结节中的应用
这项多中心回顾性研究评估了Afirma基因组测序分类器(GSC)在359个Bethesda III或IV类、以嗜酸细胞为主的甲状腺结节中的表现,这些结节均接受过细针穿刺活检和GSC检测。结果显示,Bethesda III和IV类结节的良性呼叫率分别为81%和74%,GSC在两类结节中均具有高敏感性和高阴性预测值,但Bethesda III类结节的阳性预测值较低(24%),尤其在合并桥本甲状腺炎时。结论认为GSC在嗜酸细胞性结节中表现优于早期分子检测,尤其对Bethesda IV类结节,但Bethesda III类结节的阳性预测值仍不理想。
要点
- GSC在Bethesda III和IV类嗜酸细胞性结节中良性呼叫率分别为81%和74%。
- GSC的阴性预测值在两类结节中均达99%,适合用于排除恶性。
- Bethesda III类结节合并桥本甲状腺炎时,GSC特异性与阳性预测值显著降低。
核心结论
- Afirma GSC在嗜酸细胞性甲状腺结节中具有高良性呼叫率,表现优于早期分子检测,尤其对Bethesda IV类结节。
- Bethesda III类结节的阳性预测值仍较低,合并桥本甲状腺炎时进一步降低。
研究设计与样本
- 共分析359个结节,其中57%为Bethesda III类,43%为Bethesda IV类,平均结节大小为2.0 cm。
主要发现
- Bethesda III类结节的良性呼叫率为81%,Bethesda IV类为74%。
- Bethesda III类结节中GSC的敏感性、特异性、阳性预测值、阴性预测值分别为89%、86%、24%、99%。
- Bethesda IV类结节中GSC的敏感性、特异性、阳性预测值、阴性预测值分别为94%、87%、50%、99%。
- 合并桥本甲状腺炎显著降低Bethesda III类结节的特异性和阳性预测值。
- TIRADS分类不影响Bethesda III或IV类结节的良性呼叫率或阳性预测值。
临床怎么用
- 对于Bethesda IV类嗜酸细胞性甲状腺结节,GSC的高阴性预测值有助于避免不必要的手术。
- 对于Bethesda III类结节,尤其合并桥本甲状腺炎时,GSC阳性结果需谨慎解读,因其阳性预测值较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Oncocytic cells can occur in benign and malignant thyroid nodules, posing a diagnostic challenge. This has reduced the diagnostic performance of molecular testing for indeterminate oncocytic thyroid nodules. OBJECTIVE: To evaluate the performance of Afirma genomic sequencing classifier (GSC) in thyroid nodules with Bethesda III or IV cytology and oncocytic predominance. DESIGN, SETTING, PATIENTS, AND INTERVENTION: A multicenter retrospective study was conducted in adults with Bethesda III and IV thyroid nodules showing oncocytic predominance who underwent a fine-needle aspiration biopsy and Afirma GSC testing between July 2017 and December 2023. Variables included presence of Hashimoto's thyroiditis and Thyroid Imaging Reporting and Data System (TIRADS) classification. MAIN OUTCOME MEASURES: Outcomes included benign call rate (BCR), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of Afirma GSC testing. RESULTS: Of 359 nodules (57% Bethesda III, 43% Bethesda IV) tested with Afirma GSC, the mean nodule size was 2.0 cm. BCR was 81% and 74% for Bethesda III and IV nodules, respectively. GSC sensitivity, specificity, PPV, and NPV were 89%, 86%, 24%, and 99% for Bethesda III nodules and 94%, 87%, 50%, and 99% for Bethesda IV nodules, respectively. A concurrent diagnosis of Hashimoto's thyroiditis significantly reduced the specificity and PPV in Bethesda III nodules. TIRADS classification did not affect the BCR or PPV in Bethesda III or IV nodules. CONCLUSION: Afirma GSC has a high BCR and improved performance over earlier generation molecular tests in oncocytic thyroid nodules, particularly for Bethesda IV. However, the PPV in Bethesda III nodules remains low, especially in the presence of Hashimoto's thyroiditis.
引用
- Ahmadi S, Kotwal A, Bikas A, et al. Utility of genomic sequencing classifier in managing cytologically indeterminate oncocytic thyroid nodules. J Clin Endocrinol Metab. 2026. PMID: 41655976. doi:10.1210/clinem/dgag044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。